Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Persistent activation of the Insulin-like Growth Factor 1 Receptor (IGF1R)/mammalian Target of Rapamycin (mTOR) signaling pathway is critical in hepatocellular carcinoma (HCC) development.
• MicroRNAs (miRNAs) are key regulators of gene expression and are implicated in various cancers, including HCC.

Purpose of the Study:

• To identify specific miRNAs targeting the IGF1R/mTOR pathway in HCC.
• To evaluate the therapeutic potential of single or dual miRNA intervention for HCC treatment.

Main Methods:

• Analysis of miRNA expression in HCC tissues and cell lines.
• In vitro and in vivo functional assays to assess the impact of miRNA overexpression on HCC growth and invasiveness.
• Validation of miRNA targets (IGF1R and mTOR) and pathway activity using specific agonists and ligands.

Main Results:

• miR-497 and miR-99a were found to be downregulated in HCC tissues and cell lines.
• Ectopic expression of miR-497 or miR-99a significantly inhibited HCC cell growth, invasiveness, and tumor development in vivo by repressing IGF1R and mTOR.
• The inhibitory effects were reversed by IGF1 or MHY1485, confirming pathway involvement.
• Simultaneous overexpression of both miRNAs demonstrated synergistic tumor suppression, exceeding individual effects and correlating with stronger IGF1R/mTOR repression.

Conclusions:

• miR-497 and miR-99a act as tumor suppressors in HCC by inhibiting the IGF1R/mTOR signaling pathway.
• The synergistic action of miR-497 and miR-99a offers a promising novel therapeutic strategy for molecular treatment of HCC.